PFM Health Sciences, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001442756

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q4 2025 · 76 positions · Total reported value $935.28M · Top-10 concentration 41.8% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 75.8% · 24 new · 28 cut · 39 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -4.9% · vs SPY -7.0% · Prev Value $1.14B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +2.3% · vs SPY +0.2% · Latest Value $978.49M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2025 13F filing, PFM Health Sciences, LP disclosed 76 equity positions with a combined reported value of $935.28M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 41.8% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were THC ($79.04M), LLY ($73.39M), AXSM ($45.95M). By sector, the heaviest allocations are Health Care 91.4%, Industrials 4.1%. Versus the prior quarter, allocation shifted toward Health Care (+8.8pp), Industrials (+3.3pp) and away from Consumer Staples (-1.2pp), Other (-10.7pp).

Versus the prior quarter, PFM Health Sciences, LP opened 24 new positions, trimmed 28 and fully exited 39, a turnover rate of 75.8% of positions. The portfolio's overlap with the prior quarter was 46% of names.

The largest new positions opened in Q4 2025 were GKOS ($22.77M), MDT ($20.54M), SYK ($17.87M).

Of the 39 positions fully exited versus the prior quarter, the largest were XBI ($71.88M), MCK ($55.86M), COR ($25.16M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • GKOS GLAUKOS CORP · $22.77M
  • MDT MEDTRONIC PLC · $20.54M
  • SYK STRYKER CORPORATION · $17.87M
  • UNH UNITEDHEALTH GROUP INC · $16.68M
  • DXCM DEXCOM INC · $15.09M
  • CAH CARDINAL HEALTH INC · $12.81M
  • TFX TELEFLEX INCORPORATED · $12.50M
  • GILD GILEAD SCIENCES INC · $8.72M

Fully Exited (vs previous quarter)

  • XBI SPDR SERIES TRUST · prev qtr: $71.88M · history
  • MCK MCKESSON CORP · prev qtr: $55.86M
  • COR CENCORA INC · prev qtr: $25.16M
  • ELV ELEVANCE HEALTH INC FORMERLY · prev qtr: $19.64M
  • NTRA NATERA INC · prev qtr: $18.61M
  • SPY STATE STR SPDR S&P 500 ETF T · prev qtr: $14.13M · history
  • IWM ISHARES TR · prev qtr: $13.72M · history
  • MRUS MERUS N V · prev qtr: $12.31M

Insider Transactions (Form 4)

Latest PFM Health Sciences, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

PFM Health Sciences, LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 96 US equity positions with a combined value of $1.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-69012 (status: Approved), registered 2008-04-10
  • Regulatory AUM (Form ADV): $1.27B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 2 hedge funds
  • Website: pfmhealthsciences.com

Portfolio Structure

  • 96 positions · $1.14B reported value (Q2 2026)
  • Top 10 holdings = 34.6% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 5.4%
  • Average position size: $11.89M

Sector Tilt

  • Health Care 92.9%
  • Industrials 5.1%
  • Consumer Staples 1.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 32 new, 24 added, 40 reduced, 14 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 91.4%
Technology 0.8%
Other 2.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 397.77K $79.04M 8.45%
8.45%
Reduce
2 68.29K $73.39M 7.85%
7.85%
Reduce
3 251.56K $45.95M 4.91%
4.91%
Reduce
4 145.17K $45.14M 4.83%
4.83%
Reduce
5 67.74K $33.01M 3.53%
3.53%
Reduce
6 306.51K $23.44M 2.51%
2.51%
Reduce
7 1.27M $23.18M 2.48%
2.48%
Add
8 163.20K $23.15M 2.48%
2.48%
Add
9 201.68K $22.77M 2.44%
2.44%
New
10 37.91K $21.97M 2.35%
2.35%
Add
11 246.84K $21.04M 2.25%
2.25%
Reduce
12 115.34K $21.02M 2.25%
2.25%
Reduce
13 265.52K $20.98M 2.24%
2.24%
Add
14 213.80K $20.54M 2.20%
2.20%
New
15 1.69M $19.92M 2.13%
2.13%
Reduce
16 187.83K $19.77M 2.11%
2.11%
Reduce
17 1.47M $18.47M 1.97%
1.97%
Add
18 50.85K $17.87M 1.91%
1.91%
New
19 50.54K $16.68M 1.78%
1.78%
New
20 43.21K $16.41M 1.75%
1.75%
Add
21 372.30K $15.32M 1.64%
1.64%
Reduce
22 10.65M $15.13M 1.62%
1.62%
Reduce
23 227.36K $15.09M 1.61%
1.61%
New
24 591.60K $14.80M 1.58%
1.58%
Reduce
25 360.69K $12.94M 1.38%
1.38%
Reduce
26 62.34K $12.81M 1.37%
1.37%
New
27 57.41K $12.52M 1.34%
1.34%
Reduce
28 102.39K $12.50M 1.34%
1.34%
New
29 151.45K $12.06M 1.29%
1.29%
Reduce
30 247.89K $11.48M 1.23%
1.23%
Add
31 31.16K $9.18M 0.98%
0.98%
Reduce
32 15.41K $8.73M 0.93%
0.93%
Reduce
33 71.02K $8.72M 0.93%
0.93%
New
34 50.51K $8.59M 0.92%
0.92%
New
35 107.77K $8.55M 0.91%
0.91%
Reduce
36 176.41K $8.55M 0.91%
0.91%
New
37 37.85K $8.53M 0.91%
0.91%
New
38 106.58K $8.36M 0.89%
0.89%
New
39 100.80K $8.26M 0.88%
0.88%
Add
40 32.49K $7.25M 0.78%
0.78%
Reduce
41 499.84K $7.18M 0.77%
0.77%
Reduce
42 87.55K $7.16M 0.77%
0.77%
New
43 163.97K $6.81M 0.73%
0.73%
Add
44 188.96K $6.65M 0.71%
0.71%
Add
45 42.30K $6.61M 0.71%
0.71%
New
46 13.87K $6.47M 0.69%
0.69%
Reduce
47 805.82K $6.41M 0.69%
0.69%
New
48 107.69K $5.45M 0.58%
0.58%
Reduce
49 779.62K $5.38M 0.57%
0.57%
Reduce
50 242.97K $5.10M 0.55%
0.55%
Reduce

FAQ

What did PFM Health Sciences, LP buy in 2025-Q4?

In its 2025-Q4 13F filing, PFM Health Sciences, LP reported 76 equity positions worth $935.28M in aggregate; its largest disclosed positions were THC ($79.04M), LLY ($73.39M), AXSM ($45.95M).

How large is PFM Health Sciences, LP's portfolio?

PFM Health Sciences, LP reported $935.28M of long equity holdings across 76 positions as of 2025-Q4. Top-10 holdings account for 41.8% of reported value.

What is PFM Health Sciences, LP's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/pfm-health-sciences/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →